Morphic Holding Stock News

Morphic Holding, Inc. (NASDAQ:MORF) shares gapped down prior to trading on Tuesday . The stock had previously closed at $55.32, but opened at $53.32. Morphic shares last traded at $53.98, with a volume of 965 shares. Separately, Zacks Investment Research upgraded Morphic from a sell rating to a hold rating in a research note on []

Squarepoint Ops LLC bought a new position in Morphic Holding, Inc. (NASDAQ:MORF) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 8,113 shares of the companys stock, valued at approximately $466,000. Several other hedge funds and other institutional investors have []

Nuveen Asset Management LLC lifted its stake in Morphic Holding, Inc. (NASDAQ:MORF) by 75.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 120,292 shares of the company’s stock after purchasing an additional 51,844 shares during the period. Nuveen Asset Management LLC’s holdings […]

Morphic is pursuing a multi-billion opportunity of replacing biologics modulating integrins with small molecules. The company is founded by the individual who discovered integrins and has built a uniq

CLMT, FANH, and MORF have been added to the Zacks Rank #5 (Strong Sell) List on September 16, 2021.

WALTHAM, Mass., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious ch

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -40.00% and -35.87%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Morphic Therapeutic (NASDAQ: MORF) has announced additional data from its Phase 1 trial evaluating MORF-057 for inflammatory bowel disease (IBD).  The data were shared at the Congress of European

MORF-057 well tolerated across all phase 1 cohorts

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near

Presentation will include summary safety, pharmacokinetic and pharmacodynamic data from single ascending dose (SAD), food effect and multiple ascending dose (MAD) studies

WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chr

Expanded research and development collaboration with Janssen for third integrin program

Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term Otello Stampacchia steps down, Vikas Goyal to leave Morphic Board at the end of current term

This experimental biotech has more than tripled investors' money over the past 12 months.